Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer

Neelima Vidula; Leif W Ellisen; Aditya Bardia

doi:10.18632/oncotarget.27863

Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer

Oncotarget. 2021 Jan 19;12(2):63-65. doi: 10.18632/oncotarget.27863.

Authors

Neelima Vidula¹, Leif W Ellisen¹, Aditya Bardia¹

Affiliation

¹ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Abstract

Plasma based genotyping via cell-free DNA may identify actionable mutations for potential therapeutic intervention in patients with advanced malignancies including breast cancer. In this article, we discuss recent studies using cell-free DNA testing to identify and classify somatic BRCA1/2 mutations in metastatic breast cancer, and potential future applications for the treatment of metastatic breast cancer.

Keywords: BRCA1/2; PARP inhibitor; cell-free DNA; metastatic breast cancer; plasma based genotyping.